BridgeBio Pharma ROE - Return on Equity 2018-2025 | BBIO

BridgeBio Pharma return on equity for the quarter ending March 31, 2025 was 49.43.

  • BridgeBio Pharma average return on equity for 2024 was 41.17, a 9.95% increase from 2023.
  • BridgeBio Pharma average return on equity for 2023 was 45.72, a 18.42% decline from 2022.
  • BridgeBio Pharma average return on equity for 2022 was 56.04, a 218.68% decline from 2021.

Roe - return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.

BridgeBio Pharma ROE - Return on Equity 2018-2025 | BBIO

  • BridgeBio Pharma average return on equity for 2024 was 41.17, a 9.95% increase from 2023.
  • BridgeBio Pharma average return on equity for 2023 was 45.72, a 18.42% decline from 2022.
  • BridgeBio Pharma average return on equity for 2022 was 56.04, a 218.68% decline from 2021.

Roe - return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.